Miglustat Dipharma

Miglustat, the active ingredient in Miglustat Dipharma, is a glucosylceramide synthase inhibitor presented as an oral formulation for oral use. It treats Niemann-Pick disease type C and Gaucher disease type 1 in appropriate patients.

GNH USA supplies Miglustat Dipharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and transplant centres worldwide.

Miglustat is used as substrate reduction therapy for lysosomal storage disorders, targeting the accumulation of glycosphingolipids.

Niemann-Pick disease type C: reduces glycosphingolipid buildup, helping to stabilize neurological function. Gaucher disease type 1: lowers substrate accumulation in macrophages, improving hematologic and visceral symptoms. Rare lysosomal storage disorders: may be employed off‑label as substrate reduction therapy under specialist supervision.

Miglustat may cause a range of adverse reactions, from mild gastrointestinal discomfort to rare but serious events.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may affect appetite. - Abdominal pain: cramping or discomfort in the stomach area. - Weight loss: gradual reduction in body weight. - Flatulence: increased gas production. - Taste alteration: metallic or altered taste perception.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain. - Severe hypoglycemia: low blood sugar, especially in patients with diabetes. - Allergic reactions: rash, itching, or swelling that may require medical attention. - Elevated liver enzymes: potential liver injury, monitored via blood tests. - Depression or mood changes: new or worsening psychiatric symptoms. - Seizures: rare neurologic events requiring urgent care.

Before initiating Miglustat therapy, clinicians should consider several safety measures.

Monitor liver function: obtain baseline tests and repeat periodically. Assess renal function: adjust use in patients with impaired kidneys. Evaluate gastrointestinal tolerance: counsel patients on diet and hydration. Avoid in patients with known hypersensitivity to miglustat or its excipients. Pregnancy: risk category unknown; discuss potential benefits and risks with the prescriber. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Miglustat can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may markedly reduce miglustat exposure. - Co‑administration with other substrate reduction agents: increases risk of toxicity. - Antidiabetic drugs (e.g., insulin, sulfonylureas): may potentiate hypoglycemia.

Moderate Interactions (Monitor Closely): - Warfarin: may affect INR; monitor coagulation parameters. - Antiepileptic drugs: can alter miglustat plasma levels. - Oral contraceptives: possible reduction in contraceptive effectiveness; consider additional barrier methods.